Our aim was to determine if SGLT2 inhibition might represent a valid therapeutic strategy in these individuals, as well as identify the mechanisms by which these agents might be acting to regulate hepatic steatosis in vivo. Here, SLC5A2 is linked to Hepatic steatosis.